Sitavig registered in seven European countries

BioAlliance Pharma's Sitavig (aciclovir Lauriad) has been approved for the treatment of recurrent labial herpes in the following European countries: Sweden, the UK, Spain, Italy, Denmark, Finland and Norway.

The decentralised procedure, with Sweden as Reference Member State, ended with a positive opinion for these first seven countries. Each country will now issue a national marketing authorisation in the coming weeks.

BioAlliance Pharma plans to pursue the submission of the registration dossier in other European countries as soon as the first quarter of 2013.

Access all of our latest analysis, data and forecasts - request a trial